Indeed, given the high risk of recurrent thrombotic event in APS patients, particularly those with a first unprovoked event (3), aPL results might affect the choice of the anticoagulant drug as well as the treatment duration (4–7). This evidence concerns the gene FASLG and autoimmune polyendocrinopathy.